|
“ SGLT2抑制剂终于可以证实自己的功效了！” 又一位教授刷屏了！ 美国心脏协会2020年科学年会又有重磅消息传来，A novel diabetes medication significantly reduces the risk of hospitalization for heart failure, heart attack and stroke, in patients with Type 2 diabetes and chronic kidney disease, according to late breaking research presented today at the American Heart Association’s Scientific Sessions 2020. （一种新型的糖尿病药物可以有效地减少2型糖尿病及慢性肾病患者因心衰、心脏骤停及中风而入院治疗的风险，这是来自美国心脏协会2020年科学年会的重磅科研新闻。） 01 — 来龙去脉 SGLT2 inhibitors are a class of medications that are prescribed to lower blood sugar in adultswith Type 2 diabetes. Sotagliflozin is the first dual SGLT2/1 inhibitor developed for the management of both Type 1 and Type 2 diabetes.（钠-葡萄糖协同转运蛋白2(sodium-dependent glucosetransporters 2，SGLT-2)抑制剂，可以抑制肾脏对葡萄糖的重吸收，使过量的葡萄糖从尿液中排出，降低血糖。这是一类新型抗糖尿病药物。是一种用于降低成年人2型糖尿病血糖的药物。Sotagliflozin（索格列净）是首个用于治疗1型和2型糖尿病的双SGLT2/1抑制剂。）  他的作用机制如何？ “People with Type 2 diabetes have higher rates of cardiovascular and kidney disease and more serious complications,” said lead study author Deepak L. Bhatt, M.D., M.P.H.,FAHA, executive director of interventional cardiovascular programs at Brighamand Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School. “Recent trials of other SGLT2 inhibitors have consistently shown reductions in heart failure, and we wanted to assess the safety and efficacy of sotagliflozin in adults with Type 2 diabetes and chronickidney disease.”（2型糖尿病患者一般都有较高的心血管疾病及肾脏疾病发病风险，同时也会有很多严重的并发症，该项研究的主要作者Deepak L. Bhatt医生是哈佛大学医学院，布列根女子医院心脏与血管中心教授，同时也是心血管介入治疗临床项目执行总监。他认为最新的研究结果显示SGLT2抑制剂可以持续的减少2型糖尿病患者心衰风险，我们也希望借此来评估索格列净之于2型糖尿病及慢性肾病患者的有效性及安全性）。 糖尿病管理一直是老大难 02 — 研究结果为什么令人满意？ Researchers conducted a randomized, placebo-controlled, multicenter study to investigatethe effects of sotagliflozin. In the SCORED trial, more than 10,000 people(average age 69, 45% women, 17% non-white) with Type 2 diabetes and chronic kidney disease were randomized to receive either sotagliflozin or placebo.（研究人员通过随机对照分组在多个医学中心观察索格列净服药组与安慰剂组的效果差异。在第二次研究中，超过1万名患者（其中45%为女性、17%为非白人，平均年龄为69岁）2型糖尿病患者及慢性肾病患者分别入组服用了索格列净与安慰剂。） 教授专访 There was asignificant 26% decrease in the total number of cardiovascular deaths,hospitalizations for heart failure or urgent visits for heart failure. Asignificant reduction in the total number of heart attacks and strokes wasachieved. There was a significant reduction in blood glucose levels in patientswith moderately to severely reduced kidney function. 在服用索格列净的患者中因心血管死亡的案例相比较安慰剂组下降了26%，心脏骤停及卒中的发生率均显著下降，在中重度肾脏功能受损的患者中血糖水平也有显著下降。 作用机理 Bhatt added, “Sotagliflozin is the first SGLT2 inhibitor to show a beneficial effect on stroke among patients with diabetes, suggesting that it may also affect atherosclerosis, or plaque build-up in the coronary and brain arteries.教授另外还指出索格列净是第一款有显著降低糖尿病患者卒中风险联系的SGLT2抑制剂，同时也有可能会对动脉粥样硬化的过程有疗效，或者可以影响斑块在冠状动脉及脑动脉的形成。 患者的福音 看来这应该是2型糖尿病患者的福音了！ 扫描二维码 获取医养精彩 关注作者 |
|
|
